Anthera Pharmaceuticals Inc
OTC:ANTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
FormPipe Software AB
STO:FPIP
|
SE |
|
D
|
Develia SA
WSE:DVL
|
PL |
|
D
|
Dong-A Socio Holdings Co Ltd
KRX:000640
|
KR |
|
Aquarius Engines AM Ltd
OTC:AQUEF
|
IL |
|
Jiangxi Guotai Group Co Ltd
SSE:603977
|
CN |
|
V
|
Vector Inc
TSE:2656
|
JP |
|
China Telecom Corp Ltd
HKEX:728
|
CN |
|
C
|
Colowide Co Ltd
TSE:7616
|
JP |
|
Grupo Simec SAB de CV
BMV:SIMECB
|
MX |
|
D
|
Deutsche Telekom AG
OTC:DTEGY
|
DE |
|
Access-Power & Co Inc
OTC:ACCR
|
US |
|
Shenzhen Cheng Chung Design Co Ltd
SZSE:002811
|
CN |
Anthera Pharmaceuticals Inc
EPS (Diluted)
Anthera Pharmaceuticals Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Anthera Pharmaceuticals Inc
OTC:ANTH
|
EPS (Diluted)
-$1
|
CAGR 3-Years
49%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
EPS (Diluted)
-$1
|
CAGR 3-Years
32%
|
CAGR 5-Years
27%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
Anthera Pharmaceuticals Inc
Glance View
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life threatening diseases. The company is headquartered in Hayward, California and currently employs 21 full-time employees. The company went IPO on 2010-03-02. The firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
See Also
What is Anthera Pharmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
-1.1
USD
Based on the financial report for Mar 31, 2018, Anthera Pharmaceuticals Inc's EPS (Diluted) amounts to -1.1 USD.
What is Anthera Pharmaceuticals Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
45%
Over the last year, the EPS (Diluted) growth was 89%. The average annual EPS (Diluted) growth rates for Anthera Pharmaceuticals Inc have been 49% over the past three years , 45% over the past five years .
